AMG 167 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteopenia
Conditions
Osteopenia
Trial Timeline
May 1, 2009 → Nov 1, 2009
NCT ID
NCT00902356About AMG 167 + Placebo
AMG 167 + Placebo is a phase 1 stage product being developed by Amgen for Osteopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT00902356. Target conditions include Osteopenia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00902356 | Phase 1 | Completed |
Competing Products
18 competing products in Osteopenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide + Zoledronic Acid | Eli Lilly | Approved | 85 |
| alendronate sodium | Merck | Approved | 85 |
| zoledronic acid | Novartis | Phase 3 | 77 |
| zoledronic acid vs pamidronate | Novartis | Approved | 85 |
| Zoledronic Acid + Placebo | Novartis | Phase 3 | 77 |
| BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804 | Novartis | Phase 2 | 52 |
| Placebo + ibandronate [Bonviva/Boniva] | Roche | Approved | 85 |
| ibandronate [Bonviva/Boniva] + Placebo | Roche | Phase 3 | 77 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Placebo + AMG 167 | Amgen | Phase 1 | 32 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Denosumab | Amgen | Phase 3 | 76 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Dasatinib 100 Mg Oral Tablet | Novo Nordisk | Phase 2 | 51 |
| RN564 | Pfizer | Phase 1 | 32 |
| risedronate + alendronate | Sanofi | Phase 1 | 32 |
| Menostar (Estradiol, BAY86-5435) + Raloxifene | Bayer | Phase 3 | 74 |
| tibolone + raloxifen | Organon | Approved | 80 |